Clarus AGM EIA
- UID
- IMP/IVD/2019/000296_7d8e48b2bbf49676c56431147d31862e_d3fd46d1aec0678ebe362b76bb731200
- Device class
- Class C
- Brand name
- sona Aspergillus GM LFA
- License holder
- Taevas Life Sciences Private Limited
- Approving authority
- CDSCO
- Product information
- The clarus Aspergillus Galactomannan EIA (sona Aspergillus GM LFA) is an immunoenzymatic, sandwich microplate assay used for the qualitative detection of Aspergillus galactomannan in serum and bronchoalveolar lavage (sona Aspergillus GM LFA) samples from patients at-risk for invasive aspergillosis. The clarus AGM EIA is a test which can be used as an aid in the diagnosis of aspergillosis when tested in conjunction with other diagnostic procedures such as microbiological culture, histological examination of biopsy samples, and radiographic evidence. It is intended for laboratory professional use.
Clarus AGM EIA is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/IVD/2019/000296_7d8e48b2bbf49676c56431147d31862e_d3fd46d1aec0678ebe362b76bb731200. This device is marketed under the brand name sona Aspergillus GM LFA. The license holder is Taevas Life Sciences Private Limited, and it is classified as Device Class Class C. The approving authority is CDSCO.
This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.